Categories: BioTechMedtechProduct
Revel Pharmaceuticals is a biotechnology commercializing therapeutic enzymes to degrade age associated molecule damage. We are targeting a class of pathological age associated compounds termed Advanced Glycation End Products (AGEs) which build up on long lived proteins like collagen. AGE accumulation is implicated in multiple diseases of aging, thus Revel Pharmaceuticals is strategically position to develop therapeutics across multiple indications.
Investors 2
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.03.2022 | Seed | $8.4M | - |
Mentions in press and media 3
| Date | Title | Description |
| 05.03.2023 | Интервью с Обри де Греем | Aubrey de Grey
Что такое старение? Мы можем определить его как процесс накопления молекулярных и клеточных повреждений, являющихся следствием нормального метаболизма. В то время как исследователи всё ещё плохо понимают, как метаболические п... |
| 17.03.2022 | Revel Pharmaceuticals Raises $8.4M In Seed Funding | Revel Pharmaceuticals, a San Francisco, CA-based longevity therapeutics company developing enzymes to repair damage from aging, raised $8.4M in Seed financing.
The round was led by Kizoo Technology Capital, and Starbloom Capital with partic... |
| 17.03.2022 | Kizoo Portfolio Company Revel Pharmaceuticals Announces $8.4M Seed to Develop Repairing-Based Approaches to Reversing Aging | SAN FRANCISCO, March 17, 2022 (GLOBE NEWSWIRE) -- Revel Pharmaceuticals, a longevity therapeutics company developing enzymes to repair damage from aging, announced today that it has raised $8.4M in Seed financing. The oversubscribed round w... |
Reviews 0
